Navigation Links
Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
Date:2/19/2008

NEW YORK, Feb. 19 /PRNewswire-FirstCall/ -- Cowen Group, Inc. (Nasdaq: COWN) and Cowen Healthcare Royalty Partners ("CHRP") announced today that Matthew Q. Reber has been hired as Vice President, effective immediately.

Mr. Reber is based in Connecticut and rejoins founders Gregory B. Brown, Todd C. Davis and Clarke B. Futch, the Managing Directors of CHRP, with whom he previously worked at Paul Capital Partners.

Prior to joining CHRP, Mr. Reber worked at Accretive LLC, a private investment firm. Previously, he was an associate at Paul Capital Partners in the Paul Royalty Funds, which he joined in 2005 after having been a summer associate. In addition to royalty-based investing, Matt has significant healthcare experience across a broad range of transactions, including private equity investments, public and private financings, advisory transactions and structured finance. Prior to Paul Capital Partners, Mr. Reber was an investment professional focused on the healthcare industry at Oak Hill Capital Partners and J.H. Whitney & Co. and a healthcare investment banker at Morgan Stanley.

Matt earned his MBA with honors from The Wharton School of the University of Pennsylvania, his Master of Biotechnology from The University of Pennsylvania and his BSE, magna cum laude, from Princeton University.

"We are excited to have Matt rejoin us and further strengthen our team. We are confident that his extensive experience in the health care industry, combined with his strong transactional background will enhance the capabilities and leadership of our firm," said Todd C. Davis, Co-founder and Managing Director of CHRP.

Since its inception, CHRP has continued to build and strengthen its team. In January, CHRP also announced the promotion of Paul J. Hadden to Vice President and John A. Urquhart to Associate.

About Cowen Healthcare Royalty Partners

Cowen Healthcare Royalty Partners manages an investment program that invests principally in commercial-stage biopharmaceutical products and companies. CHRP seeks to invest in companies and acquires royalty interests in end-user sales of commercial-stage, or near commercial-stage medical products such as pharmaceuticals, biotechnology products and medical devices. CHRP, based in Stamford, CT, is led by a team of investors who bring complementary skills and backgrounds to bear on the evaluation and execution of these investments.

For further information, contact:

Cowen Healthcare Royalty Partners

177 Broad St., Suite 1101

Stamford, CT 06901

(646) 562-1000

http://www.cowenroyalty.com

About Cowen Group, Inc.

Cowen Group, Inc., through Cowen and Company, LLC and Cowen International Limited, provides investment banking services, including underwriting and other capital raising solutions, equity research, sales, trading and mergers and acquisitions advice, to emerging growth companies in sectors including healthcare, technology, media and telecommunications and consumer.


'/>"/>
SOURCE Cowen Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
2. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
3. The Ensign Group, Inc. Declares Quarterly Dividend of $0.04 Per Share
4. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System
5. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
6. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
7. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
8. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)
9. MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 2008 UBS Healthcare Services Conference
10. Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
11. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... CA (PRWEB) , ... May 26, 2016 , ... ... and manufacturing company, today announced several positive developments that position the Company for ... a result of the transaction, Craig F. Kinghorn has been appointed Chairman of ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board of Investment’s New ... San Francisco. Located at booth number 7301, representatives from the Thai Government, research ... the Thai biotechnology and life sciences sector. , Deputy Secretary General of ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... for information (RFI) issued by the Office of the National Coordinator for Health ... experience, and determines if clinically relevant data were available when and where it ...
(Date:5/25/2016)... FL (PRWEB) , ... May 25, 2016 , ... Lady ... eight she tore her cruciate ligament in her left knee. Lady’s owner Hannah sought ... a central Florida board-certified veterinary surgeon, to repair her cruciate ligament and help with ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
Breaking Biology News(10 mins):